ArticleMolecules (Basel, Switzerland)2025
Chitosan-Oligosaccharide-Bearing Biphasic Calcium Phosphate Bone Cement: Preparation and Angiogenic Activity In Vitro.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Although calcium phosphate bone cement has some advantages (it is easy to form, self-curing, and does not produce heat), some disadvantages remain that limit its clinical application. Therefore, the question of how we can modify CPC and further improve the various properties of calcium phosphate bone cement is a current research hotspot. In this paper, the preparation conditions and technology of biphasic calcium phosphate (BCP) were optimized; chitosan oligosaccharide (COSM) with MW ≤ 3000 Da was added to the optimal formulation of biphasic calcium phosphate cement particles, and its physical and chemical properties were characterized. The results showed that BCP bone cement carrier for clinical operations was successfully constructed by the high-temperature solid-state reaction method, and COSM-BCP bone cement particles were obtained by loading COSM drugs with an angiogenesis effect. Its formula is biphasic calcium phosphate powder with the molar ratio of α-TCP/β-TCP of 1. The curing time of the prepared BCP particles is 24 ± 1 min, the compressive strength is 29.58 ± 1.89 MPa, and the porosity reaches 52.09%. The loaded COSM can be released continuously and stably in vitro, and has the effect of promoting angiogenesis. The safety evaluation of COSM-BCP bone cement particles and the preliminary pharmacodynamic study of its angiogenesis in vitro provide a promising clinical application basis for the development of drug-loaded biological bone substitute materials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.